secwatch / observer
8-K filed August 5, 2021, 7:59 PM ET ticker BDTX CIK 0001701541
leadership confidence high sentiment neutral materiality 0.65

Black Diamond appoints interim CMO and new CSO; CMO and CSO depart

Black Diamond Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Elizabeth Buck

Chief Scientific Officer
BDTX · Black Diamond Therapeutics, Inc.
Effective
2021-08-11
Successor
Christopher Roberts
Filed
August 5, 2021, 7:59 PM ET
Effective August 11 , 2021, Dr. Buck succeeds Christopher Roberts, Ph.D., Chief Scientific Officer, who notified the Company on July 12, 2021 of his resignation from the Company to assume the role of chief executive officer at another company.
Appointed (interim)

Karsten Witt

Interim Chief Medical Officer
BDTX · Black Diamond Therapeutics, Inc.
Effective
2021-08-04
Successor
Rachel Humphrey
Filed
August 5, 2021, 7:59 PM ET
Dr. Witt succeeds Rachel Humphrey, M.D., Chief Medical Officer, effective August 4, 2021.
Departed

Rachel Humphrey

Chief Medical Officer
BDTX · Black Diamond Therapeutics, Inc.
Effective
2021-08-04
Successor
Karsten Witt
Filed
August 5, 2021, 7:59 PM ET
Dr. Witt succeeds Rachel Humphrey, M.D., Chief Medical Officer, effective August 4, 2021.
Departed

Christopher Roberts

Chief Scientific Officer
BDTX · Black Diamond Therapeutics, Inc.
Effective
2021-08-11
Successor
Elizabeth Buck
Filed
August 5, 2021, 7:59 PM ET
Dr. Buck succeeds Christopher Roberts, Ph.D., Chief Scientific Officer, who notified the Company on July 12, 2021 of his resignation from the Company to assume the role of chief executive officer at another company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Elizabeth Buck was appointed as Chief Scientific Officer at Black Diamond Therapeutics, Inc..

Action
appointed
Role
Chief Scientific Officer
Exact text from the filing
Effective August 11 , 2021, Dr. Buck succeeds Christopher Roberts, Ph.D., Chief Scientific Officer, who notified the Company on July 12, 2021 of his resignation from the Company to assume the role of chief executive officer at another company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Karsten Witt was appointed as Interim Chief Medical Officer at Black Diamond Therapeutics, Inc..

Action
appointed
Role
Interim Chief Medical Officer
Exact text from the filing
Dr. Witt succeeds Rachel Humphrey, M.D., Chief Medical Officer, effective August 4, 2021.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Rachel Humphrey departed as Chief Medical Officer at Black Diamond Therapeutics, Inc..

Action
succeeded
Role
Chief Medical Officer
Exact text from the filing
Dr. Witt succeeds Rachel Humphrey, M.D., Chief Medical Officer, effective August 4, 2021.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Roberts resigned as Chief Scientific Officer at Black Diamond Therapeutics, Inc..

Action
resigned
Role
Chief Scientific Officer
Exact text from the filing
Dr. Buck succeeds Christopher Roberts, Ph.D., Chief Scientific Officer, who notified the Company on July 12, 2021 of his resignation from the Company to assume the role of chief executive officer at another company.
View on SEC.gov

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-21-100444
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.